ResMed, Inc. (RMD) Misses Q3 EPS by 2c
ResMed, Inc. (NYSE: RMD) reported Q3 EPS of $0.33, $0.02 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $314.8 million versus the consensus estimate of $326.32 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
- H.B. Fuller (FUL) Misses Q2 EPS by 1c, Raises Low End of FY EPS Guidance
- Accenture (ACN) Reports In-Line Q3 EPS; Boosts FY16 EPS Outlook
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!